Other News To Note
Friday, February 17, 2012
Cleveland BioLabs Inc., of Buffalo, N.Y., said results of the first structural and biophysical study of Toll-like receptor 5 (TLR5)/flagellin interaction help to decipher the molecular mechanisms underlying TLR5 recognition and signaling by CBLB502, an optimized derivative of bacterial flagellin and the company's candidate in development as a radiation countermeasure and a cancer therapeutic agent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.